EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies

Mei Xie, Lingrui Kong, Guojia Li, Yan Chen, Lin Hou, Jian Hou iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2025. Verfasst von Mei Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Marine Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 173 Literaturangaben. Gefördert von: This review is supported by the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (No. GZC20231506); Special Project of Qingdao Science….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic, relapsing skin ailment characterized by intense itching and diverse clinical manifestations. Its pathogenesis is complex, involving genetic, microbial, and immunological factors. Recently, significant therapeutic advancements have been made in AD, including topical phosphodiesterase‐4 (PDE‐4) inhibitors, Janus kinase (JAK) inhibitors, and biologics targeting cytokines and signaling molecules such as Interleukin‐13 (IL‐13), Interleukin‐31(IL‐31), thymic stromal lymphopoietin (TSLP), and OX40/OX40L. This review comprehensively demonstrates the genetic, microbial, and immunological factors underlying AD, with a particular emphasis on the gut‐skin axis. Furthermore, it summarizes recently approved drugs and potential therapeutic agents currently under clinical trials. Besides, the review highlights the emerging role of the gut‐skin axis in AD pathogenesis and the breakthroughs in novel targeted therapies. These include inhibitors of IL‐13 and IL‐31, which have shown remarkable efficacy in reducing disease severity and improving quality of life in patients with moderate‐to‐severe AD. Additionally, the review contains the potential of targeting the OX40/OX40L pathway, which holds promise for future therapeutic development. Based on these advancements, the review provides an outlook on the potential for individualized treatment strategies or precision medicine approaches in AD, aiming to optimize therapeutic outcomes and patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansAnimalsCytokinesPhosphodiesterase 4 InhibitorsThymic Stromal LymphopoietinJanus Kinase Inhibitors

Stichwörter der Autor:innen

atopic dermatitisgut microbiota dysbiosistargeted Inhibitors

Substanzen

CytokinesPhosphodiesterase 4 InhibitorsThymic Stromal LymphopoietinJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Research Institute of Marine Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Qingdao, Shandong, China.
  • Qingdao Academy of Chinese Medical Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, Shandong, China.

ORCID-Profile: Jian Hou

Förderung

  • This review is supported by the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (No. GZC20231506); Special Project of Qingdao Science…

Zitieren

APA

Xie, M., Kong, L., Li, G., Chen, Y., Hou, L., & Hou, J. (2025). Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies. Drug Development Research. https://doi.org/10.1002/ddr.70161

Vancouver

Xie M, Kong L, Li G, Chen Y, Hou L, Hou J. Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies. Drug Development Research. 2025. doi:10.1002/ddr.70161

BibTeX
@article{Xie2025,
  author = {Xie, Mei and Kong, Lingrui and Li, Guojia and Chen, Yan and Hou, Lin and Hou, Jian},
  title = {Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70161}
}
Kostenlos starten →